Post by myocat on Jun 24, 2017 10:03:06 GMT -5
Please, delete if this article had been posted
www.sfvbj.com/news/2017/jun/23/mannkind-sees-prescriptions-bump/
Prescriptions for Valencia biotech MannKind Corp.’s lead product reached over 380, according to contributor Spencer Osborne at Seeking Alpha, a stock market insight website. This was the highest number of prescriptions written for the Mannkind’s inhalable insulin Afrezza, since the company launched its internal marketing department about a year ago.
Prescription numbers for Afrezza at its peak was around 600, when MannKind was in a marketing partnership with Sanofi, a French pharmaceutical company. However, since Sanofi pulled out of the partnership about a year and a half ago, the script numbers have been in the low 300’s.
MannKind (MKND) shares jumped early Friday but then closed down 2 cents, or less than 2 percent, to $1.50 on the Nasdaq.
www.sfvbj.com/news/2017/jun/23/mannkind-sees-prescriptions-bump/
Prescriptions for Valencia biotech MannKind Corp.’s lead product reached over 380, according to contributor Spencer Osborne at Seeking Alpha, a stock market insight website. This was the highest number of prescriptions written for the Mannkind’s inhalable insulin Afrezza, since the company launched its internal marketing department about a year ago.
Prescription numbers for Afrezza at its peak was around 600, when MannKind was in a marketing partnership with Sanofi, a French pharmaceutical company. However, since Sanofi pulled out of the partnership about a year and a half ago, the script numbers have been in the low 300’s.
MannKind (MKND) shares jumped early Friday but then closed down 2 cents, or less than 2 percent, to $1.50 on the Nasdaq.